WATERTOWN, Mass.—EyePoint, Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company and developer of therapeutics for patients with serious retinal diseases, announced financial results for the second quarter ended June 30, 2026, and highlighted recent corporate developments. The company reported Q2 2026 revenue of $0.5 million, down from $5.3 million compared with the same period last year. The larger loss reflected increased spending on Duravyu phase 3 trials and manufacturing scale-up, while cash and investments declined to $180 million. Duravyu (vorolanib intravitreal insert) is an investigational, sustained-delivery treatment designed to treat serious retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
The decrease in second quarter revenue was primarily driven by the recognition of remaining deferred revenue related to the company’s 2023 agreement for the license of Yutiq product rights, the company noted. Yutiq (fluocinolone acetonide intravitreal implant) is a sterile, non-bioerodible micro-insert designed to treat chronic, non-infectious uveitis affecting the posterior segment of the eye. License and collaboration revenue remained EyePoint’s sole reported revenue stream during the quarter, as the company said it generated no product sales.
“With topline data from our pivotal phase 3 Lugano wet AMD trial expected this month, followed by Lucia in the fourth quarter, and enrollment now completed in our pivotal phase 3 DME program, we continue to execute across our clinical programs,” said Jay S. Duker, MD, president and CEO of EyePoint. “The Lugano and Lucia data readouts represent transformative advancement in the wet AMD landscape, potentially positioning Duravyu as the foundational treatment option for sustained patient care.”
Operating expenses for the quarter ended June 30, 2026, totaled $97.9 million versus $67.6 million for the corresponding period in 2025. This increase was primarily attributable to ongoing Duravyu Phase 3 clinical trials for wet AMD and DME and scale-up of the company’s commercial manufacturing facility.
Net non-operating income totaled $2.9 million and net loss was $94.5 million compared with a net loss of $59.4 million for the corresponding period in 2025.
Cash, cash equivalents, and marketable securities as of June 30, 2026, totaled $180 million compared with $223 million as of March 31, 2026. The company said it expects the cash, cash equivalents, and marketable securities as of June 30, 2026, will enable it to fund operations into the fourth quarter of 2027 beyond key milestones for the phase 3 wet AMD program in 2026.
In July 2026, EyePoint announced the appointment of Tarek S. Hassan, MD, as senior vice president, chief strategic science officer. Dr. Hassan also serves as a member of the executive leadership team.
